apl-581

APL-581 is a **small molecule drug** developed to act as a dual inhibitor of **bromodomain-containing protein 4 (BRD4)** and **Janus kinase (JAK)** family enzymes. It is designed to modulate epigenetic and kinase-driven pathways relevant to oncology, specifically for the treatment of neoplasms and hematologic disorders. The drug was originally developed by **Aptose Biosciences** and later licensed for further development to **OHM Oncology**. Its mechanism of action involves inhibiting BRD4, a chromatin reader protein that regulates transcription of genes involved in cancer cell growth, and inhibiting JAK kinases, which are key mediators in cytokine signaling and hematologic malignancies. Development of APL-581 has been discontinued, and it did not progress beyond preclinical development[1][5][7][11].